FibroGen, Inc. Board of Directors

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Dr. Elizabeth Bearby Pharm.D.

Dr. Elizabeth Bearby Pharm.D.

Senior VP of Regulatory, Biometrics, Scientific Communications & Clinical Project Management

Ms. Christine L. Chung

Ms. Christine L. Chung

Senior Vice President of China Operations

Ms. Tricia Stewart

Ms. Tricia Stewart

Chief People Officer

David DeLucia

David DeLucia

Vice President of Corporate FP&A and Investor Relations

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.